Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALERT CML: Asciminib as Initial Therapy With Addition of Lower Dose TKIs for CML
NCT05143840Phase 2Active, not recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Apr 2022
- Primary completion
- Feb 2032
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of asciminib in chronic myeloid leukemia (CML) (3 arms), sponsored by University of Alabama at Birmingham. Primary endpoints: Deep Molecular Response at 24 months and Digital Droplet PCR at 2 years. Started Apr 2022; status: active, not recruiting.
02
Drugs
asciminib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT05143840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05143840.